Previous studies with VX-680 already showed [60], [115], that BCR-ABL inhibitory VX-680 concentrations do not appear to be necessary to induce anti-CML activity in human Ph+ cell lines suggesting that the activity of VX-680 in CML is mediated at least partly by Aurora- and not by ABL- inhibition. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.